Patent ID: 8236758

Claim:
A method of treatment of diabetes or reduction in pancreatic β-cells, said method comprising administering a pharmaceutical composition to a subject in need thereof, the pharmaceutical composition including at least one of the following active ingredients (a) to (f): (a) a polypeptide having an amino acid sequence encoded by DNA having a base sequence as set forth in SEQ. ID. No. 1 or SEQ. ID. No. 4; (b) a polypeptide having an insulin secretion inducing action and/or an action of increasing the number of pancreatic β-cells, and having an amino acid sequence in which one amino acid has been substituted, deleted and/or added to an amino acid sequence encoded by DNA having a base sequence as set forth in SEQ. ID. No. 1 or SEQ. ID. No. 4; (c) a fragment of the polypeptide in (a) or (b) having an insulin secretion inducing action and/or an action of increasing the number of pancreatic β-cells, said fragment comprising the amino acid sequence set forth in SEQ ID NO:10 or SEQ ID NO:11 or SEQ ID NO:12; (d) a polypeptide having an amino acid sequence as set forth in SEQ. ID. No. 3 or SEQ. ID. No. 6; (e) a polypeptide having an insulin secretion inducing action and/or an action of increasing the number of pancreatic β-cells, and having an amino acid sequence in which one amino acid has been substituted, deleted and/or added to an amino acid sequence as set forth in SEQ. ID. No. 3 or SEQ. ID. No. 6; and (f) a fragment of the polypeptide in (d) or (e) having an insulin secretion inducing action and/or an action of increasing the number of pancreatic β-cells, said fragment comprising the amino acid sequence set forth in SEQ ID NO:10 or SEQ ID NO:11 or SEQ ID NO:12.